

Ovarian tissue freezing: slow freezing versus vitrification

Claus Yding Andersen, Professor, MSc, DMSc

Laboratory of Reproductive Biology

University Hospital Copenhagen,

University of Copenhagen

Copenhagen, Denmark

E-mail: yding@rh.dk

“Cryobiology and cryopreservation of human gametes and embryos”

ESHRE Campus workshop, Athens, Greece, September 25 -26th 2009

Rationale and perspectives of cryopreserving and transplanting ovarian tissue

- ❖ **Fertility can be maintained after curing disease where treatment may harm ovarian function**
- ❖ **And will lead to menstrual cycles and an endogenous hormone production in contrast to other fertility preserving methods**

Chemotherapy and gonadotoxicity

Risk of inducing detrimental effects on the gonad

- ❖ The specific chemotherapeutic drug used
- ❖ Dose of chemotherapy
- ❖ Duration of chemotherapy
- ❖ Age of woman

Candidate diseases for ovarian cryopreservation

Cancer patients

Breast cancer

Cervical cancer

Hodgkin's lymphoma

Non-Hodgkin's lymphoma

Osteosarcoma

Ewing's sarcoma

Wilm's tumor

Bone marrow transplant patients

Leukemia (?)

Aplastic anemia

Sickle cell anemia

Adjunctive oophorectomy

Endometriosis

Autoimmune diseases

Collagen vascular diseases (SLE)

Acute Glomerulonephritis


Behcet's disease

Ovarian diseases


BRCA-1 and -2 mutations

Turner's Syndrome

Only the ovarian cortex is cryopreserved



Preparation of human ovarian tissue for cryopreservation



CRYOPRESERVATION PROTOCOL

(KLT. Schmidt et al., Hum Reprod. 2003)

- ❖ **Cryoprotectant: 1.5 mol/l Ethyleneglycol
0.1 mol/l Sucrose
10 mg/ml HSA**

- ❖ **Temperature profile:**
 1. **Equilibration - rotation (1-2 °C in 30 min)**
 2. **- 2 °C/min indtil – 9 °C.**
 3. **Manuel seeding**
 4. **– 0,3 °C/min until – 40 °C**
 5. **–10 °C/min until – 140 °C**
 6. **Liquid nitrogen (– 196 °C)**

Percentage of morphological healthy follicles before and after cryopreservation

6 ovaries in each group

Cryopreservation media:


I : Leibowitz medium, 10 % FCS & 1.5 M DMSO

II : Leibowitz medium, 10 % FCS & 1.5 M Ethyleneglycol

III : PBS, 0.1 M sucrose & 1.5 M DMSO

IV: **PBS, 0.1 M sucrose & 1.5 M Ethyleneglycol**


	I	II	III	IV
BEFORE	97 ± 0.5	97 ± 0.7	97 ± 0.8	97 ± 1.3
AFTER	32 ± 11	31 ± 11	47 ± 11	63 ± 8



Freeze-thawed mouse ovary implanted under the kidney capsule of an ovariectomized mouse for 2 weeks

**Primordial follicles in the ovarian cortex
from a 12 year old girl**






Human ovarian tissue transplanted under the skin of immunodeficient ovariectomised mice for 4 weeks


Transplanting ovarian cortical tissue to ovariectomised immunodeficient nude mice for four weeks

Tissue from 42 women (49 transplantations) showed surviving follicles and resulted in no apparent disease development in all cases



Frozen thawed human ovarian cortex implanted under the skin of ovariectomized SCID mice for 4 weeks

**Transport of ovarian tissue – 6 year old girl
20 hours on ice prior to cryopreservation**



Prior to transplantation

**Human ovarian tissue transplanted under the skin
of ovariectomised SCID mice for 4 weeks**


Equilibration in cryoprotectant for 30 min at 0 °C on a shaking table



Lessons learned: temperature at equilibration

Number of patients with cryopreserved ovarian tissue at University Hospital of Copenhagen

(Sep 2009: 385 patients)



Three step thawing procedure

I
0,75 M Ethyleneglycol
0,2 M sucrose in PBS


10 min

II
0,1 M sucrose
in PBS

10 min



III
PBS

10min





Orthotopic transplantation of ovarian tissue



Transplantation of frozen/thawed ovarian tissue: successful pregnancies

- ❖ Belgium 2004 – ♀
- ❖ Israel 2005 – ♀
- ❖ Denmark 2007 – ♀
- ❖ Belgium 2007 – ♀
- ❖ Denmark 2008 – ♂
- ❖ Denmark 2008 – ♀


All healthy babies



Transplantation of frozen/thawed ovarian cortex with cryopreservation immediately after recovery

Patient	Diagnosis	Age (years)	Proportion of tissue transplanted (%)	Lifespan (months)	No. remaining cryopreserved cortex
1	Non-Hodgkin's Lymphoma	32	A: 20 B: 35	A: 45 B: 21 →	15
2	Hodgkin's Lymphoma	28	A: 40 B: 30	A: 54 B: 6 →	7
3	Hodgkin's Lymphoma	25	A: 60 B: 40	A: 26 B: 37 →	0
4	Paroxymal Nocturnal haemogloburi	19	33	17 →	24
5	Aplastic anaemia	25	40	12 →	10

Mean and individual FSH concentrations following ovarian autotransplantation in 12 women



**Overall results of assisted reproduction after
transplantation of frozen/thawed ovarian tissue
(September 2009)**

	Total
No. cycles	
Follicles asp.	
No. oocytes	
No. Fertilized	
No. transferred	
Pos. hCG	
Children born	



Vitrification of human ovarian cortical tissue

General considerations:

- ❖ The type and mixture of the cryoprotectants
- ❖ The size of pieces of tissue to be cryopreserved
- ❖ The speed of cooling (direct emission in liquid N₂)
- ❖ The need of clinical verification – time period

Diffusion distances of cryoprotectants in ovarian tissue

Very different from conditions in oocytes and embryos



Slow freezing versus vitrification


Slow freezing and vitrification of human ovarian cortical tissue

General considerations:

- ❖ The texture of human cortical tissue is very different to most animal tissue
- ❖ which may affect the penetration rate of the cryoprotectants and optimal conditions
- ❖ and models developed by the use of animal tissue may not be used clinically in connection with **human tissue and *vice versa***

Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue


Experimental set-up



Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue

Step	DMSO (mol/l)	PrOH (mol/l)	Ethylene glycol (mol/l)	PVP	Temp (°C)
1	0.35	0.35	0.35	-	Room
2	0,7	0,75	0,75	-	Room
3	1,4	1,5	1,5	10 %	+ 4

Duration of each step was either 5 or 10 min



Controlled-rate freezing in cryopreservation of human ovarian tissue

❖ PrOH-protocol

1,5 mol/l propanediol, 0,1 mol/l sucrose, 25 mg/ml
HSA in PBS

Equilibration at room temperature

❖ Ethyleneglycol-protocol

1,5 mol/l ethyleneglycol, 0,1 mol/l sucrose, 10 mg/ml
HSA in PBS

Equilibration at +4 °C

Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue

Results:

- ❖ Based on tissue from 20 women and using morphological characteristics evaluated by light and electron microscopy
- ❖ The study concluded that vitrification was comparable to slow freezing in terms of preserving follicles in human ovarian tissue
- ❖ However, it appears that the ovarian stroma retained a better morphological integrity after vitrification

Clinical implication – Vitrification is not yet applied in a clinical setting

Human ovarian tissue vitrification versus conventional freezing: morphological, endocrinological, and molecular biological evaluation

Step	DMSO (M)	PrOH (M)	Ethylene-glycol (M)	Acet-amide (M)	Temp (°C)	Time (min.)
1	12,5 % of final concentration				Room	5
2	25 %				Room	5
3	50 %				+ 4	15
4	2,62	1,31	0,0075	2,60	+ 4	15

The cortical tissue is plunged directly into liquid nitrogen

Controlled-rate freezing in cryopreservation of human ovarian tissue


- ❖ DMSO-protocol
1,5 mol/l, 0,1 mol/l sucrose, 10 % SSS in Leibovitz
medium

Equilibration ice cold

Human ovarian tissue vitrification versus conventional freezing: morphological, endocrinological, and molecular biological evaluation

- ❖ During a 16 day long culture period there were no difference in oestradiol and progesterone secretion
- ❖ PCR detection of GAPDH mRNA showed a significant reduced expression in the vitrified cortical tissue

❖ Morphology:




A number of other studies also suggest that there is not too big a difference between vitrification and slow-freezing

- ❖ The primordial follicle is pretty resistant to freezing (as is the mature oocyte and testicular tissue)
- ❖ The oocyte and the granulosa cells are metabolically relative inactive at the early resting stage
- ❖ Easy penetrable cryoprotectants is required at conditions which minimize toxicity (low temperature)



The size of the frozen/thawed cortical pieces used for transplantation

- ❖ Most vitrification studies use pieces of cortical tissue considerably smaller than those employed clinically
- ❖ Keros V et al. 2009 used pieces of: 1 x 1-2 x 5-8 mm
- ❖ Isachenko V et al. 2009 used pieces of 0,3 – 1 x 1-1,5 x 0,7 – 1 mm
- ❖ Small pieces of cortical tissue facilitate quick penetration of cryoprotectant and build on experience from oocytes and embryos, but



Vitrification of ovarian tissue: factors that needs clarification before implimentation in a clinical setting

- ❖ **The importance of the size of the cortical fragments for subsequent functioning of the tissue**
- ❖ **How to obtain sufficient cooling rates in a clinical setting**

Survival of primordial follicles after grafting fresh or frozen-thawed cortical tissue from sheep ovaries to SCID mice

Slow-freezing protocol: 1,5 M DMSO, 10% FSC, Leibowitz medium

Graft type (group no.)	Primordial follicles	
	No. \pm SEM	% of control
1) Control	192 \pm 47	
2) Fresh	68 \pm 11	35
3) Frozen-thawed	54 \pm 12	28

The vast majority of follicles are lost following transplantation

Conclusions

- ❖ Ovarian cryopreservation including transport of tissue prior to cryopreservation is now a clinical option
- ❖ In combination with ART results from Denmark suggests that ovarian cryopreservation do present a clinical relevant way of preserving fertility
- ❖ Efficacy of vitrification of ovarian tissue in a clinical setting still requires development
- ❖ Research to enhance transplantation efficiency is warranted

Collaborators

University Hospital of Copenhagen: Laboratory of Reproductive Biology:

Anders Nyboe Andersen

Anne Loft

The Fertility Clinic

Lene Lundwald

Christian Ottesen

Department of Gynaecology

Anne Grete Byskov

Mikkel Rosendahl

Kirsten Tryde Schmidt

Tiny Roed

Inga Husum

Marjo Westerdahl

Stine Gry Kristensen

Claus Yding Andersen

University Hospital of Aarhus:

Erik Ernst

Margit Dueholm

Ditte Trolle

The Fertility Clinic

Department of Gynaecology

University Hospital of Odense:

Lars Westergaard †

Per Emil Rasmussen

The Fertility Clinic

Department of Gynaecology

**The Danish Medical
Research Council**

**The Danish Cancer
Foundation**